PROTACs for Collateral Degradation: Is It Time to Back Up the Bus?

Abstract

Off-target effects are usually undesirable in drug development, but for some PROTACs and other degraders, they may be advantageous. Specifically, this can be so when the activities of multiprotein complexes are more important than just the targeted protein of interest.